CA Patent

CA2831600C — Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol

Assigned to Novartis AG · Expires 2020-04-21 · 6y expired

What this patent protects

A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.

USPTO Abstract

A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.

Drugs covered by this patent

Patent Metadata

Patent number
CA2831600C
Jurisdiction
CA
Classification
—
Expires
2020-04-21
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.